GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about change in Management
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has appointed Mr. Vishwanath Swarup as Commercial Head - General Medicines, effective 9th July 2025. Vishwanath brings extensive experience in business strategy and commercial leadership, most recently serving as Chief Operating Officer at Bharat Serums and Vaccines. He has also held leadership roles at Abbott, Max Bupa, McKinsey & Company, Pfizer Consumer, and Unilever, and holds an MBA from Kellogg School of Management, Northwestern University. The appointment has been disclosed under SEBI Listing Regulations (Regulation 30) regarding change in senior managerial personnel.
This is a routine senior-level hire to strengthen the General Medicines commercial function. No material impact on shareholders or stock price is expected as it is a mid-to-senior management appointment rather than a CEO/CFO change.